New Marketplace

Making Bundled Payments Work: Leveraging the CMS DRG Experience

Article · May 10, 2018

Both the Centers for Medicare and Medicaid Services (CMS) and private insurers are moving toward bundled payments for episodes of care. We believe that the health care industry has an opportunity to make this movement much more effective and useful by drawing on more than 30 years of experience with an earlier form of bundled payment: Diagnosis Related Groups (DRGs), which created a system of fixed payments for inpatient services associated with specific diagnoses and procedures.

CMS (then the Health Care Financing Administration) adopted the DRG system for prospective payment for Medicare patients in 1983 to curb skyrocketing hospital costs, and states and private payers followed suit, with variations to fit their needs. DRGs represented a radical shift in how health care was paid for. The new system did incentivize hospitals to become more efficient in coordinating care and controlling costs for inpatients. However, DRGs did not extend to services rendered outside the hospital, and therefore did not encourage integrated, coordinated care overall. Nor did DRGs in themselves provide any incentive to avoid readmissions, though CMS has recently begun to address this drawback by withholding payments for certain types of readmissions that it deems avoidable.

Hospital Utilization Before and After DRG Introduction

  Click To Enlarge.

CMS and private insurers are now experimenting with a more comprehensive form of bundled payments, where a single reference price is established for all health care services provided to a patient during a clinical episode of care that extends both before and after the hospitalization formerly covered by a DRG.

The primary aim of these extended and comprehensive payments is to create incentives to encourage the provision of integrated and coordinated high-value patient care, resulting in higher quality and lower cost. These models require teamwork and integration among all providers of care, including hospitals, outpatient services, and home health. These longer-term and more inclusive bundled payments also are intended to eliminate avoidable readmissions during the time covered by the bundle.

The CMS Innovation Center is currently piloting the following:

Many aspects of these bundled payment models are positive, including:

  • The focus on episodes of care that drive the majority of Medicare spending (episodes included BPCI account for roughly 70% of Medicare dollars)
  • Bundling of Medicare Parts A and B, post-acute care services, and readmission (in various configurations) to promote greater integration and service coordination
  • The extension of episode length beyond the index hospitalization (by 30, 60, or 90 days), which provides incentives to improve quality and reduce costs by reducing avoidable complications
  • Establishing requirements for ongoing quality monitoring to ensure that providers deliver care that is not only efficient, but also effective in the long term

Four lessons from DRGs

However, it would behoove CMS to draw on its successes with DRGs in structuring the reimbursement of these (and any forthcoming) bundles. Specifically, we believe the agency should consider the following steps:

  1. Set a prospective, reality-based, national benchmark payment rate, and adjust it for local factors such as patient case mix and geographic cost of doing business. We discuss payment rates further in the four-quadrant analysis below. The goal is to allow providers to focus on improving quality and lowering costs, rather than on managing administrative complexity. This undue administrative burden can be alleviated if a single reference price is set based on the actual total costs incurred by the highest-quality and lowest-cost providers. Currently, all but one of the four models being tested under BPCI require Medicare to continue making the usual fee-for-service payments to providers (with all of the attendant paperwork), with adjustments made later against the provider-specific target price determined by CMS. A single payment rate would remove this reconciliation step and the need for additional fund transfers to or from the provider.
  2. Update price benchmarks annually instead of quarterly. Unlike DRG base rates, which are updated annually, BPCI episode prices to date have been updated quarterly based on actual national average change in Medicare spending across the 48 bundles. This ongoing uncertainty about target prices (and thus the potential savings for providers) has made for a challenging business case for providers who are making investments to improve the value of patient care. We support the use of annual benchmarks for all bundles, as is the case for CJR bundles and is being proposed for the recently announced BPCI Advanced program (subject to a possible adjustment during the semiannual reconciliation process).
  3. Reward an absolute level of performance, instead of the degree of improvement. DRG payments are fixed, so a hospital’s DRG margin depends on its level of efficiency (and increasingly, also on the quality of care provided). In contrast, under the current Medicare bundle models, separate target prices are set for each hospital and include a discount to all participating providers, regardless of the value they already provide. Moreover, the shared savings structure of most bundles, where target prices are derived from either the hospital’s historical spending or a combination of hospital and region-specific spending, continues to favor high-cost facilities and regions, while penalizing already efficient providers. As shown in Figure 1, under the current reimbursement arrangements, a high-value care provider (Medical Center 1) will see significantly less upside from improving the value of patient care in the bundle than a low-value care provider (Medical Center 2). Perhaps, more important, why would we want to pay a high-cost, low-value provider more than a low-cost, high-value provider?
  4. Make provider participation in bundles mandatory, instead of voluntary, to do away with “pilot program” mentality. DRGs were effective because they were mandatory. Recognizing that providers need time to set up the infrastructure required to do bundles well, we would suggest that CMS focus initial efforts on its top three to five most expensive procedures and its top three to five most expensive medical conditions and roll those out over a 1 to 2-year period.

A Better Way to Set Prices

We believe that the four-quadrant value analysis, pioneered by The Dartmouth Institute and recently extended by the Commonwealth Fund, can help CMS create bundled pricing based on real costs, while establishing the right types of provider incentives.

Figure 1 shows how this analysis would work, using the cost and quality of coronary artery bypass graft procedures as an example. The analysis allows CMS to identify providers that already deliver high-value care (above-average quality at below-average cost, in the upper left quadrant). Using this provider group as a benchmark, CMS could establish a single, national reference price for the bundle (for example, based on the 80th percentile of actual costs for the high-value group). In doing so, CMS would steer clear of penalizing high-value providers, while creating a strong change incentive for those providers who find themselves outside the high-value quadrant.

This approach also carries the strongest cost savings potential, since the incentive (and potential) for improvement would be particularly strong for high-cost organizations. To ensure that low-quality organizations do not get rewarded for simply being low cost, we propose a 5% quality withhold to create an additional incentive to improve the quality of patient care. To that end, all delivery organizations would initially receive 95% of the base payment amount. Providers with above-average outcomes would receive an additional 5% (bringing their total to 100% of the base payment amount), while payment to providers with below-average outcomes would be capped at 95% of the base payment amount (red dotted line in Figure 1).

Example 4-Quadrant Analysis and Price Setting for a Single-Procedure Bundle - Lessons Learned from DRG Implementation

Figure 1. Click To Enlarge.

As we can see, the potential for improvement at Medical Center 2 under our proposed model, which uses a specific benchmark, is much greater than under a model that rewards improved performance.

Given its clout and experience, CMS has a unique opportunity to lead the health system toward high-value care. By leveraging lessons learned from DRG implementation, aided by the four-quadrant value analysis, CMS can set itself and providers up for real success in implementing new payment models.

New call for submissions ­to NEJM Catalyst

Now inviting longform articles


A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.

Learn More »

More From New Marketplace
Elements of a Sustainable Complex Care Management Contract

Sustainable Financing for Complex Care Management Is Critical to a Value-Driven Health Care System

Care management should be payer-agnostic at its core.

Comparison of Certain Model Features in Blue Cross NC Blue Premier vs Next-Generation ACO Model vs BCBSMA Alternative Quality Contract

Engineering a Rapid Shift to Value-Based Payment in North Carolina: Goals and Challenges for a Commercial ACO Program

We believe North Carolina can be a model for the nation.

Small Molecule Drugs Facing Generic Competition - Orphan and Non-Orphan Drugs - Orphan Drug Act

It’s Time to Reform the Orphan Drug Act

Three proposals for improving the law to reflect 21st-century drug development practices.

Three-Part Pricing of PCSK9 Inhibitors

A New Model for Pricing Drugs of Uncertain Efficacy

Are we paying too much for new drugs before we know how well they work? This innovative pricing model proposes postponing major rewards until efficacy is established — which could help both patients and payers while still paying back investments on the most effective drugs.

what does quality measurement in health care mean

Buzz Survey Report: Addressing the Problems of Quality Measurement

An independent NEJM Catalyst report sponsored by University of Utah Health on patient involvement in quality measurement.

Average HOOS and Average KOOS for patients undergoing hip and knee replacement at CJRI

Building a “Hospital-within-Hospital” Model for Joint Replacements

The Connecticut Joint Replacement Institute has demonstrated that formerly competing independent providers can unite on a common vision to yield drastic improvements in quality, safety, and costs.

Discharge Rates and Follow-Up Internval Dashboard for One Provider at MGH Dermatology

A Successful Pilot to Improve Access by Adjusting Discharge and Follow-Up Rates

Actionable data and modest financial incentives can help motivate clinicians to adjust their behavior around scheduling follow-up appointments.

Cautious Optimism That Value-Based Reimbursement Will Become Primary Revenue Model

Survey Snapshot: What Would Accelerate the Adoption of Value-Based Care?

NEJM Catalyst Insights Council members weigh in on the barriers and path forward to value-based health care.

Strongwater08_pullquote primary care value proposition and disruptive innovation

The Evolution of Primary Care: Embracing Innovation While Protecting the Core Value

Primary care must leverage disruptive innovations to ensure that patients receive first-access, comprehensive, coordinated, continuous care that is woven into a seamlessly integrated system.

Berns01_pullquote nephrologists dialysis facility joint venture conflicts of interest

Dialysis-Facility Joint-Venture Ownership — Hidden Conflicts of Interest

Despite potential benefits, joint ventures between nephrologists and dialysis companies raise legal and ethical concerns because of participants’ conflicts of interest and lack of transparency.


A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.

Learn More »


Value Based Care

199 Articles

Curbing Health Care Spending: The Provider’s…

Health care costs have historically grown at about 2% faster than income in the United…

Medicare and Medicaid

122 Articles

A Collaborative Model to Expand Medicaid…

How managing the benefit coverage expansion for the treatment of HCV in New Mexico was…

Vertical Integration and Bold Experimentation

Four points on improving value in health care via vertical integration and aggressive experimentation.

Insights Council

Have a voice. Join other health care leaders effecting change, shaping tomorrow.

Apply Now